Int J Stem Cells.  2015 Nov;8(2):209-218. 10.15283/ijsc.2015.8.2.209.

Autologous Stem Cells Transplantation in Egyptian Patients with Liver Cirrhosis on Top of Hepatitis C Virus

• Al Tayeb H
• El Dorry A
• Amer N
• Mowafy N
• Zimaity M
• Bayoumy E
• Saleh SA

• KMID: 2380815
• DOI: http://doi.org/10.15283/ijsc.2015.8.2.209

Abstract

BACKGROUND AND OBJECTIVES
Use of pluripotent stem cells is an ideal solution for liver insufficiencies. This work aims is to evaluate the safety and feasibility of autologous stem cells transplantation (SCT) in Egyptian patients of liver cirrhosis on top of hepatitis C virus (HCV). SUBJECTS AND RESULTS: 20 patients with HCV induced liver cirrhosis were divided into 2 groups. Group I: included 10 patients with liver cirrhosis Child score > or =9, for whom autologous stem cell transplantation was done using granulocyte colony stimulating factor (G-CSF) for stem cells mobilization. Separation and collection of the peripheral blood stem cells was done by leukapheresis. G-CSF mobilized peripheral blood mononuclear cells (G-CSF PB-MNCs) were counted by flow cytometry. Stem cell injection into the hepatic artery was done. Group II: included 10 patients with HCV induced liver cirrhosis as a control group. Follow up and comparison between both groups were done over a follow up period of 6 months. The procedure was well tolerated. Mobilization was successful and the total number of G-CSF PB-MNCs in the harvests ranged from 25x106 to 191x106. There was improvement in the quality of life, serum albumin, total bilirubin, liver enzymes and the Child-Pugh score of group I over the first two-three months after the procedure.
CONCLUSION
SCT in HCV induced liver cirrhosis is a safe procedure. It can improve the quality of life and hepatic functions transiently with no effect on the life expectancy or the fate of the liver cirrhosis.

Keyword

Autologous; HCV; Liver cirrhosis; Stem cells; Transplantation

MeSH Terms

Bilirubin
Child
Colony-Stimulating Factors
Flow Cytometry
Follow-Up Studies
Granulocyte Colony-Stimulating Factor
Granulocytes
Hepacivirus*
Hepatic Artery
Hepatitis C*
Hepatitis*
Humans
Leukapheresis
Life Expectancy
Liver Cirrhosis*
Liver*
Pluripotent Stem Cells
Quality of Life
Serum Albumin
Stem Cell Transplantation
Stem Cells*
Transplantation
Bilirubin
Colony-Stimulating Factors
Granulocyte Colony-Stimulating Factor
Serum Albumin

Reference

References

1. Sukhikh GT, Shtil AA. Stem cell transplantation for treatment of liver diseases: from biological foundations to clinical experience (review). Int J Mol Med. 2003; 11:395–400. PMID: 12579347.

2. Haydon GH, Neuberger J. Liver transplantation of patients in end-stage cirrhosis. Baillieres Best Pract Res Clin Gastroenterol. 2000; 14:1049–1073. DOI: 10.1053/bega.2000.0146.

3. Keeffe EB. Liver transplantation: current status and novel approaches to liver replacement. Gastroenterology. 2001; 120:749–762. DOI: 10.1053/gast.2001.22583. PMID: 11179248.

4. Rosen HR. Disease recurrence following liver transplantation. Clin Liver Dis. 2000; 4:675–689. DOI: 10.1016/S1089-3261(05)70132-X.

5. Piscaglia AC. Stem cells, a two-edged sword: risks and potentials of regenerative medicine. World J Gastroenterol. 2008; 14:4273–4279. DOI: 10.3748/wjg.14.4273. PMID: 18666313. PMCID: 2731176.

6. Luk JM, Wang PP, Lee CK, Wang JH, Fan ST. Hepatic potential of bone marrow stromal cells: development of in vitro co-culture and intra-portal transplantation models. J Immunol Methods. 2005; 305:39–47. DOI: 10.1016/j.jim.2005.07.006. PMID: 16150456.

7. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, Low WC, Largaespada DA, Verfaillie CM. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 2002; 418:41–49. DOI: 10.1038/nature00870. PMID: 12077603.

8. Schächinger V, Erbs S, Elsässer A, Haberbosch W, Hambrecht R, Hölschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Süselbeck T, Assmus B, Tonn T, Dimmeler S, Zeiher AM. REPAIR-AMI Investigators. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med. 2006; 355:1210–1221. DOI: 10.1056/NEJMoa060186. PMID: 16990384.

9. Okumoto K, Saito T, Haga H, Hattori E, Ishii R, Karasawa T, Suzuki A, Misawa K, Sanjo M, Ito JI, Sugahara K, Saito K, Togashi H, Kawata S. Characteristics of rat bone marrow cells differentiated into a liver cell lineage and dynamics of the transplanted cells in the injured liver. J Gastroenterol. 2006; 41:62–69. DOI: 10.1007/s00535-005-1723-8. PMID: 16501859.

10. Cholongitas E, Papatheodoridis GV, Vangeli M, Terreni N, Patch D, Burroughs AK. Systematic review: The model for end-stage liver disease--should it replace Child-Pugh’s classification for assessing prognosis in cirrhosis? Aliment Pharmacol Ther. 2005; 22:1079–1089. DOI: 10.1111/j.1365-2036.2005.02691.x. PMID: 16305721.

11. Mimeault M, Hauke R, Batra SK. Stem cells: a revolution in therapeutics-recent advances in stem cell biology and their therapeutic applications in regenerative medicine and cancer therapies. Clin Pharmacol Ther. 2007; 82:252–264. DOI: 10.1038/sj.clpt.6100301. PMID: 17671448.

12. Sakaida I, Terai S, Nishina H, Okita K. Development of cell therapy using autologous bone marrow cells for liver cirrhosis. Med Mol Morphol. 2005; 38:197–202. DOI: 10.1007/s00795-005-0298-z. PMID: 16378227.

13. Yannaki E, Anagnostopoulos A, Kapetanos D, Xagorari A, Iordanidis F, Batsis I, Kaloyannidis P, Athanasiou E, Dourvas G, Kitis G, Fassas A. Lasting amelioration in the clinical course of decompensated alcoholic cirrhosis with boost infusions of mobilized peripheral blood stem cells. Exp Hematol. 2006; 34:1583–1587. DOI: 10.1016/j.exphem.2006.06.012. PMID: 17046578.

14. Mohamadnejad M, Alimoghaddam K, Mohyeddin-Bonab M, Bagheri M, Bashtar M, Ghanaati H, Baharvand H, Ghavamzadeh A, Malekzadeh R. Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. Arch Iran Med. 2007; 10:459–466. PMID: 17903050.

15. Gordon MY, Levicar N, Pai M, Bachellier P, Dimarakis I, Al-Allaf F, M’Hamdi H, Thalji T, Welsh JP, Marley SB, Davies J, Dazzi F, Marelli-Berg F, Tait P, Playford R, Jiao L, Jensen S, Nicholls JP, Ayav A, Nohandani M, Farzaneh F, Gaken J, Dodge R, Alison M, Apperley JF, Lechler R, Habib NA. Characterization and clinical application of human CD34+ stem/progenitor cell populations mobilized into the blood by granulocyte colony-stimulating factor. Stem Cells. 2006; 24:1822–1830. DOI: 10.1634/stemcells.2005-0629. PMID: 16556705.

16. Picardi M, De Rosa G, Selleri C, Scarpato N, Soscia E, Martinelli V, Ciancia R, Rotoli B. Spleen enlargement following recombinant human granulocyte colony-stimulating factor administration for peripheral blood stem cell mobilization. Haematologica. 2003; 88:794–800. PMID: 12857559.

17. Becker PS, Wagle M, Matous S, Swanson RS, Pihan G, Lowry PA, Stewart FM, Heard SO. Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells. Biol Blood Marrow Transplant. 1997; 3:45–49. PMID: 9209740.

18. Gaia S, Smedile A, Omedè P, Olivero A, Sanavio F, Balzola F, Ottobrelli A, Abate ML, Marzano A, Rizzetto M, Tarella C. Feasibility and safety of G-CSF administration to induce bone marrow-derived cells mobilization in patients with end stage liver disease. J Hepatol. 2006; 45:13–19. DOI: 10.1016/j.jhep.2006.02.018. PMID: 16635534.

19. Terai S, Ishikawa T, Omori K, Aoyama K, Marumoto Y, Urata Y, Yokoyama Y, Uchida K, Yamasaki T, Fujii Y, Okita K, Sakaida I. Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Stem Cells. 2006; 24:2292–2298. DOI: 10.1634/stemcells.2005-0542. PMID: 16778155.